title: Interstitial cystitis/bladder pain syndrome and glycosaminoglycans replacement therapy.
abstract: Interstitial cystitis/bladder pain syndrome (IC/BPS) is a debilitating chronic disease characterized by discomfort or recurrent abdominal and pelvic pains in the absence of urinary tract infections. Its symptomatology includes discomfort, increased bladder pressure, sensitivity and intense pain in the bladder and pelvic areas, increased voiding frequency and urgency, or a combination of these symptoms. For these reasons, this pathology has a very negative impact on quality of life. The etiology of IC/BPS is still not well understood and different hypotheses have been formulated, including autoimmune processes, allergic reactions, chronic bacterial infections, exposure to toxins or dietary elements, and psychosomatic factors. The finding of an effective and specific therapy for IC/BPS remains a challenge for the scientific community because of the lack of a consensus regarding the causes and the inherent difficulties in the diagnosis. The last recent hypothesis is that IC/BPS could be pathophysiologically related to a disruption of the bladder mucosa surface layer with consequent loss of glycosaminoglycans (GAGs). This class of mucopolysaccharides has hydrorepellent properties and their alteration expose the urothelium to many urinary toxic agents. It has been hypothesized that when these substances penetrate the bladder wall a chain is triggered in the submucosa. In order to improve the integrity and function of the bladder lining, GAG layer replenishment therapy is widely accepted as therapy for patients with IC/BPS who have poor or inadequate response to conventional therapy. Currently, Chondroitin sulfate (CS), heparin, hyaluronic acid (HA), and pentosan polysulphate (PPS), and combinations of two GAGs (CS and HA) are the available substances with different effectiveness rates in patients with IC/BPS. There are four different commercially available products for GAG replenishment including CS, heparin, HA and PPS. Each product has different concentrations and dosage formulations. Recently, a combination of CS and HA is the latest commercially available product with promising results.
authors.affiliation: Interstitial Cystitis Referral Center, Catholic University, Rome, Italy.
authors.forename: Mauro
authors.initials: M
authors.lastname: Cervigni
keywords: Bladder pain syndrome; glycosaminoglycan replacement (GAG replacement); interstitial cystitis (IC); multimodal therapy
references.citation: J Urol. 1996 Jul;156(1):45-8
references.pmid: 8648835
references.citation: Urology. 2003 Dec;62(6):976-82
references.pmid: 14665339
references.citation: BJU Int. 2005 Nov;96(7):1063-6
references.pmid: 16225529
references.citation: Eur Urol. 2008 Jan;53(1):60-7
references.pmid: 17900797
references.citation: BJU Int. 2009 Jan;103(1):56-60
references.pmid: 18778342
references.citation: Urology. 2012 Jun;79(6):1220-4
references.pmid: 22516357
references.citation: Int Urogynecol J. 2012 Sep;23(9):1193-9
references.pmid: 21904840
references.citation: J Urol. 1993 Sep;150(3):845-8
references.pmid: 7688432
references.citation: Int Urogynecol J. 2012 Dec;23(12):1715-20
references.pmid: 22576327
references.citation: Can Urol Assoc J. 2014 Sep;8(9-10):E610-4
references.pmid: 25295131
references.citation: J Urol. 1987 Sep;138(3):503-7
references.pmid: 2442415
references.citation: J Urol. 1991 Apr;145(4):732-5
references.pmid: 2005689
references.citation: Urology. 2002 Mar;59(3):329-33
references.pmid: 11880064
references.citation: Eur Urol. 2010 Jan;57(1):35-48
references.pmid: 19733958
references.citation: Urology. 2005 Apr;65(4):654-8
references.pmid: 15833501
references.citation: J Urol. 2008 Jan;179(1):177-85
references.pmid: 18001798
references.citation: Urol Clin North Am. 1994 Feb;21(1):93-100
references.pmid: 7904388
references.citation: Eur Urol. 2012 Jan;61(1):29-53
references.pmid: 21920661
references.citation: Int Urogynecol J. 2011 Apr;22(4):401-5
references.pmid: 20938644
references.citation: World J Urol. 1994;12(1):3-10
references.pmid: 8012413
references.citation: J Urol. 2007 Apr;177(4):1390-4
references.pmid: 17382739
references.citation: Urology. 2010 Oct;76(4):804-9
references.pmid: 20494413
references.citation: Urology. 1990 Jun;35(6):552-8
references.pmid: 1693797
references.citation: Eur Urol. 2005 Mar;47(3):393-7; discussion 397
references.pmid: 15716206
references.citation: Acta Biomater. 2015 Jun;19:66-75
references.pmid: 25818949
references.citation: Int Urogynecol J. 2012 Sep;23(9):1187-92
references.pmid: 22569687
references.citation: J Reprod Med. 2011 Sep-Oct;56(9-10):405-9
references.pmid: 22010524
references.citation: Eur Urol. 2007 Jun;51(6):1534-40; discussion 1540-1
references.pmid: 17383810
references.citation: Int Urogynecol J Pelvic Floor Dysfunct. 2008 May;19(5):717-21
references.pmid: 18097627
references.citation: J Urol. 2011 Jun;185(6):2162-70
references.pmid: 21497847
references.citation: Scand J Urol Nephrol. 2005;39(2):143-7
references.pmid: 16032779
references.citation: Can J Urol. 2002 Feb;9(1):1454-8
references.pmid: 11886599